Financial Review: Kite Pharma (KITE) versus Affimed N.V. (AFMD)

Kite Pharma (NASDAQ: KITE) and Affimed N.V. (NASDAQ:AFMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.


This table compares Kite Pharma and Affimed N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kite Pharma -1,117.44% -59.56% -48.86%
Affimed N.V. -978.31% -73.85% -59.02%

Earnings & Valuation

This table compares Kite Pharma and Affimed N.V.’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Kite Pharma $32.14 million 319.87 -$341.06 million ($6.87) -26.17
Affimed N.V. $3.99 million 23.13 -$36.26 million ($0.92) -2.28

Affimed N.V. has higher revenue, but lower earnings than Kite Pharma. Kite Pharma is trading at a lower price-to-earnings ratio than Affimed N.V., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Kite Pharma and Affimed N.V., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kite Pharma 0 10 7 0 2.41
Affimed N.V. 0 2 2 0 2.50

Kite Pharma presently has a consensus target price of $93.20, suggesting a potential downside of 48.16%. Affimed N.V. has a consensus target price of $5.38, suggesting a potential upside of 155.95%. Given Affimed N.V.’s stronger consensus rating and higher possible upside, analysts plainly believe Affimed N.V. is more favorable than Kite Pharma.

Institutional and Insider Ownership

87.7% of Kite Pharma shares are held by institutional investors. Comparatively, 42.3% of Affimed N.V. shares are held by institutional investors. 14.0% of Kite Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Kite Pharma has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Affimed N.V. has a beta of 3.65, suggesting that its share price is 265% more volatile than the S&P 500.


Kite Pharma beats Affimed N.V. on 7 of the 13 factors compared between the two stocks.

About Kite Pharma

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

About Affimed N.V.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply